Syndax Announces First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613 for the Treatment of Adults with Relapsed/Refractory Acute Leukemias
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
| (NASDAQ: SNDX) | Delayed: 13.19 +0.04 (0.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.15 | 52 Week High | $18.03 | |||
| Open | $13.06 | 52 Week Low | $8.97 | |||
| Day High | $13.20 | P/E | N/A | |||
| Day Low | $13.05 | EPS | $0.00 | |||
| Volume | 37,424 | |||||
